Ochre Bio Taiwan Ltd
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl
The content above was translated by Ai
Founded Year
2021
Unified Business No.
90531036
Status
Active
Number of Employees
8
Total capital
40,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ochre Bio is a biotech company focused on chronic liver disease therapeutics, aiming to eliminate the need for liver transplants. Their platform integrates human liver data, AI‑driven genomics, and in‑house validation using perfused human liver tissue to uncover novel disease pathways and drug targets.
The content above was translated by Ai
Corporate Video
